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Objectives. This study determined the effects of inhaled nitric
oxide (NO) on load-independent indexes of normal human left
ventricular (LV) function.
Background. Inhaled NO is a potent and selective pulmonary
vasodilator. However, when it is used in patients with congestive
heart failure, the decrease in pulmonary vascular resistance
(PVR) is often associated with an increase in pulmonary capillary
wedge pressure. NO has been shown to have a negative inotropic
action, but it is not known whether it affects LV chamber function
when delivered by inhalation.
Methods. Eleven subjects (51 to 69 years old) with normal LV
function (mean ejection fraction 72% [range 60% to 80%]) were
studied. Four patients had concomitant coronary artery disease.
Pressure-volume loop recordings were used to determine end-systolic
and end-diastolic pressure-volume and preload recruitable stroke
work relations. NO was delivered at 20 ppm for 10 min. In an
additional group of patients with normal LV function, PVR (n 5 5)
and NO metabolites (n 5 9) were measured.
Results. There was no effect of inhaled NO on steady state LV
pressures, volumes, contractility, contraction duration, active
relaxation (time constant of relaxation, peak negative first deriv-
ative of left ventricular pressure), diastolic compliance or PVR.
NO metabolites (methemoglobin and nitrate) were present in
the LV cavity at the same concentration as right atrial venous
blood, suggesting inactivation of free NO before arrival in the
LV chamber. This study had a power of 0.995 to detect a 5%
change in contractility (slope of preload recruitable stroke
work relation) for alpha 5 0.05, based on the multiple linear
regression model used.
Conclusions. These results indicate that 20 ppm of inhaled NO
does not have significant effects on normal LV function. This lack
of effect may be due in part to rapid inactivation of free NO in
transit to the heart.
(J Am Coll Cardiol 1997;30:49–56)
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Nitric oxide (NO) is involved in the regulation of vascular tone,
neurotransmission, mediation of the inflammatory response
(1) and the modulation of myocardial function (2–5). Because
of its binding to plasma proteins (especially hemoglobin) and
its rapid conversion to higher oxides of nitrogen in the
presence of oxygen, the half-life of free NO in blood is very
short (6). Administration of NO inhalation usually results in
pulmonary vascular selectivity without significant systemic
effects. Inhaled NO has been used to reduce elevated pulmo-
nary vascular resistance (PVR) in patients after cardiac surgery
(mitral valve replacement [7,8], heart transplantation [9] and
repair of congenital heart disease [10]). Its use is not limited to
cardiac intensive care. It has been successfully used in general
intensive care in the management of adult respiratory distress
syndrome (11).
Inhaled NO has also been shown (12–15) to be useful in
lessening pulmonary hypertension related to congestive heart
failure in patients awaiting heart transplantation. However, the
decrease in PVR in this group of patients is usually accompa-
nied by an increase in pulmonary capillary wedge pressure.
This elevation may not be without consequence, as pulmonary
edema during inhalation of NO has been reported (16) in these
patients.
Despite evidence of a negative inotropic role of NO in
modulating left ventricular (LV) contractility in animal prep-
arations (3,17,18) and humans (4,5), the mechanism of the
elevation in pulmonary wedge pressure during NO inhalation
in patients with left heart failure has not been defined previ-
ously. Inotropic effects would be expected to be minimal when
NO is inhaled, due to rapid inactivation of free NO by
hemoglobin (6). Although the elevation in pulmonary wedge
pressure has been ascribed (12,14) to alterations in loading
conditions, there has been no previous evaluation of LV
chamber performance using load-insensitive indexes of LV
function during administration of inhaled NO.
The aim of this study was to determine the effects of inhaled
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NO on steady state hemodynamic variables and load-
independent indexes of contractility and relaxation in humans
with normal LV function.
Methods
Patients. The study was approved by the St. Vincent’s
Hospital Research Ethics Committee. Eleven patients with
normal LV function and no history of myocardial infarction or
clinical heart failure were studied after routine coronary
angiography performed for evaluation of chest pain. All pa-
tients gave informed written consent. Eleven patients under-
went pressure-volume recordings; nine subsequent patients
had NO metabolites measured, and of these, five also had
pulmonary vasodilator response to inhaled NO assessed. Cor-
onary angiography was performed by using amidotrizoic acid
(Urografin, Scherring) contrast medium. Pressure-volume
loop acquisition followed diagnostic coronary angiography by
;15 to 20 min.
The effect of inhaled NO on LV mechanics was studied in
the first subgroup of 11 patients with a mean age of 58.3 years
(range 51 to 69). All patients had normal LV function deter-
mined by single-plane contrast ventriculography (LV ejection
fraction $60% and no segmental wall motion abnormalities).
Mean ejection fraction was 72.3% (range 60% to 80%). Six of
the 11 patients were men. Four patients had angiographic
coronary artery disease (triple-vessel in one patient, double-
vessel in one and single-vessel in two patients). No patient had
valvular dysfunction. All patients were normotensive at the
time of study. No patient gave a history of reversible or chronic
pulmonary disease. Pulmonary vasodilator response to inhaled
NO was assessed by right heart catheterization in an additional
group of five patients with similar baseline characteristics
(mean age 65.4 years [range 58 to 75] and normal LV function:
mean ejection fraction 74.5% [range 61% to 86%]). NO
metabolites were measured in nine patients, five of whom also
had pulmonary vasodilator response measured.
Inhaled NO delivery system. Inhaled NO was delivered in
spontaneous respiration by way of a close-fitting nonrebreath-
ing mask (Downs CPAP mask 9002, Vital Signs Inc.). The
mask was positioned before the baseline period and left in
place until the entire study was completed. Medical air was
delivered during the 5-min control periods before and after
administration of inhaled NO. NO was supplied in cylinders
containing 1,000 ppm in nitrogen (CIG Hytec, Australia). This
was mixed with medical air in a custom-built gas mixing panel
(CIG, Australia) and delivery was adjusted to administer
20 ppm of NO for 10 min. We used 20 ppm because previous
studies (12,19) have shown a flat dose response down to at least
10 ppm and the maximal hemodynamic effect in our earlier
study (15) was seen at 20 ppm, although it was not significantly
different from the effect at 10 ppm. That previous study (15),
using the same delivery system as that in the present study,
confirmed an elevation in pulmonary wedge pressure associ-
ated with decreased pulmonary vascular resistance in patients
with LV dysfunction. Because of the short duration of action of
inhaled NO, many investigators have noted extremely rapid
reversal of its hemodynamic (9,10,12,15) and oxygenation
(9,11) effects on cessation of its inhalation. Accordingly, in our
study, we performed control measurements after delivery of
inhaled NO 2 to 5 min after cessation of NO delivery.
Data acquisition. Pressure measurements were obtained
with a high fidelity micromanometer (2F, Millar SPC-360,
Millar Instruments) and control unit (Millar TBC-500) with
custom-modified regulated power supply to maintain electrical
stability. Volume measurements were derived with a 7F,
12-pole conductance pigtail catheter (Webster 7212-08, Web-
ster Lab Inc.) coupled to a Leycom signal processor (Sigma-5,
Cardiodynamics, Rijnsburg, The Netherlands). Conductance
catheter volumes were calibrated with the patient isocentered
with the use of single-plane contrast ventriculography and a
radiopaque sphere of known diameter. Before insertion, the
conductance catheter was flushed with heparin and the pres-
sure transducer was electrically adjusted to zero after soaking
in normal saline solution. The pressure catheter was inserted in
the volume catheter lumen and 5% dextrose/heparin (10 U/ml)
was infused at a constant slow rate to prevent intraluminal
thrombus formation.
To obtain a series of pressure-volume loops for derivation
of cardiac function, LV preload was altered by intermittent
inferior vena cava occlusion (IVCO) performed with use of a
7F balloon occlusion catheter (Cordis 530000A-15565, Cordis
Corporation) inflated with 30 to 35 ml of CO2. Each IVCO run
continued for ;10 to 15 cardiac cycles. Data were displayed
on-line at a sampling rate of 250 Hz with high frequency noise
filtering cutoff at 50 Hz, 20 dB/decade. Data were then
analyzed with customized software.
Measurements. Steady state pressure and volume were
recorded before, during and after administration of inhaled
NO. Intermittent IVCO was performed every 2 min during
these three states. Data acquisition captured all five segmental
volume signals from the conductance catheter, which were
summed to display uncalibrated volume data during the study
period. After study, each calibrated segmental volume wave-
form was examined to exclude those that corresponded to
aortic or valve placement, or those that had a poor signal to
noise ratio. After a calibrated total volume signal was obtained,
Abbreviations and Acronyms
dP/dt 5 first derivative of left ventricular pressure
EDPVR 5 end-diastolic pressure-volume relation
ESPVR 5 end-systolic pressure-volume relation
IVCO 5 inferior vena cava occlusion
LV 5 left ventricle, left ventricular
NO 5 nitric oxide
PRSWR 5 preload recruitable stroke work relation
PVR 5 pulmonary vascular resistance
T, tau 5 time constant of relaxation
V 5 volume intercept (V0 5 volume at zero pressure; V130 5
volume at 130 mm Hg; V0SW 5 volume at zero stroke work;
V10,000 5 volume at 10,000 mm Hgzml)
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control period steady state average minimal and maximal
volumes were obtained, and recalibrated against the minimal
and maximal volumes obtained at ventriculography performed
during diagnostic cardiac catheterization. The original calibra-
tion file was modified with the gain and offset adjustments to
yield a final calibration file that was used in all subsequent data
analyses.
Steady state variables included heart rate, cardiac output,
LV systolic pressure, end diastolic pressure (immediately
before the a wave), peak positive first derivative of left
ventricular pressure (dP/dt), peak negative dP/dt, time con-
stant of relaxation (T, tau), duration of contraction and
end-systolic and end-diastolic volumes. Steady state analysis
was based on analysis of multiple signal-averaged consecutive
pressure-volume loops, in most cases including three to five
complete respiratory cycles. Tau was determined by using an
exponential least squares regression analysis of pressure com-
mencing at peak negative dP/dt and continuing for a further
80 ms (20). The time of electromechanical systole was defined
as the period from the midpoint of the electrocardiographic
QR wave to the point of peak relaxation (peak negative dP/dt)
corresponding to end-ejection. This period was used as a
measure of duration of contraction (21).
The LV contractile state was measured by using both the
end-systolic pressure-volume relation (ESPVR) (22) and the
preload recruitable stroke work relation (PRSWR, the relation
between stroke work and end-diastolic volume) (23). ESPVR
was defined by a least squares linear regression of the end-
systolic pressure on end-systolic volume for consecutively
decreasing loops during IVCO, yielding a slope (end-systolic
elastance) and volume axis intercept (V0, intercept at zero
pressure). End-systole was defined from the pressure-volume
loop contour as the point of maximal pressure to volume ratio
(the line of maximal slope joining the loop origin and the
upper left corner of a loop). End-systolic pressure and volume
are the measures taken at that point (24). The end-systolic
points for ESPVR regression were obtained by an iterative
method (24) starting with V0 5 0 at the first iteration. For
ESPVR, both V0 and the volume at a pressure of 130 mm Hg
(V130) are reported. PRSWR was determined by least squares
linear regression analysis of stroke work on end-diastolic
volume for consecutive pressure-volume loops during IVCO.
Results are expressed as the slope, volume at zero stroke work
(V0SW) and volume at a stroke work of 10,000 mm Hgzml
(V10,000). The volume references V130 and V10,000 were used
because the corresponding pressure and stroke work values
were close to the respective mean values during early IVCO
runs in this patient group. Individual IVCO loop series where
the correlation coefficient for linear regression analysis was less
than 0.80 were excluded from further analysis. Poor correlation
often occurred because ventricular ectopic activity made linear
analysis of consecutive pressure-volume loops meaningless.
End-diastolic pressure-volume relations (EDPVR) were
defined after IVCO by using a linear model (25). End-diastolic
points were derived from the last third of diastole from IVCO
loops in expiration (25,26). Two diastolic points (an end-
diastolic point taken immediately before the a wave and a
point occurring on the same loop 10% of the filling volume
before that end-diastolic point) were defined per beat similar
to the method described by Lui et al. (25). This defines a
period in diastole that reflects LV diastolic properties during
slow LV filling. Although the slope of this regression expresses
an elastance, the results are usually reported as the inverse,
which is chamber compliance (27). The equation for diastolic
compliance (CDia) therefore is V 5 CDiaP 1 VoDia; where
VoDia 5 volume at zero pressure. Subjects who had suitable
IVCO runs in each measurement state (before, during and
after inhaled NO) and r .0.75 for linear regression estimation
of individual diastolic compliance were included. The mean
correlation coefficient for linear determination of diastolic
properties across the studies used was 0.91. Previous studies
(26) have shown that a linear description of diastolic compli-
ance is simpler than and fits data as well as exponential curves.
Serum methemoglobin and nitrate levels were measured in
a subgroup of nine patients. Simultaneous LV cavity and right
atrial samples were drawn before and at the end of the 10-min
delivery of 20 ppm of inhaled NO. Methemoglobin was
measured by using spectrophotometric technique on an auto-
mated analyzer (Radiometer ABL-520, Copenhagen, Den-
mark). Serum nitrates were determined by first adding nitrate
to toluene in the presence of sulfuric acid before assay by
chromatography with use of a benchtop gas chromatograph/
mass spectrometer (Hewlett-Packard 5970 MSD).
Five of those nine patients underwent right heart catheter-
ization to measure the effects of 20 ppm of inhaled NO on
mean pulmonary artery pressure, pulmonary capillary wedge
pressure and PVR in the presence of normal LV function.
PVR was calculated as the difference between mean pulmo-
nary artery pressure and pulmonary wedge pressure divided by
cardiac output (determined by Fick method). The result was
multiplied by 80 to determine PVR in units of dyneszszcm25.
Statistics. Steady state measurements were averaged in
each time period for each patient. When multiple recordings
were taken during an experimental period, the mean recording
was taken as being representative. Repeated measures analysis
of variance was used to determine the significance of differ-
ences for each steady state variable (pressure, volume and time
derivatives) among the three study periods (before, during and
after inhaled NO). Post-test comparisons were made with the
Student-Newman-Keuls test. Results before and during in-
haled NO for PVR and NO metabolites were compared by
using paired t tests (Primer of Biostatistics: The Program v4.0,
McGraw-Hill). Multiple linear regression analysis with dummy
coding to account for individual differences was used for
determination of ESPVR, PRSWR and diastolic compliance
models for the periods before and during inhaled NO. We used
multivariate analysis because it has been shown (28) to be a
valid alternative to analysis of variance and to permit coding of
interaction between individual differences and treatment ef-
fect. As the volume axis intercepts for ESPVR and PRSWR
are calculated arithmetically from the final regression equa-
tion, the p values reported for the effect of inhaled NO on
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volume intercepts are those determined by dummy coding for
effect of inhaled NO on the regression constant (pressure axis
intercept). Similarly, p values for regression slopes are re-
ported after coding for the effect of inhaled NO in the same
equation. Regression models were computed by using SPSS for
Windows 6.1 (SPSS Inc).
The power of the study was determined on the basis of
multiple linear regression models for PRSWR, ESPVR and
EDPVR, as load-independent indexes were the main area of
interest in this study. From that model, after coding for
individual differences, the power for PRSWR was 0.995 based
on a 5% change in contractility (slope of PRSWR) from
baseline, computed by using the standard error of the coeffi-
cient for the slope of PRSWR in the nine patients with data
before and during inhaled NO, with use of paired t tests, with
a 5 0.05. The respective powers for ESPVR and EDPVR for
a 5% change in elastance were 0.651 and 0.816. A two-tailed p
value ,0.05 was taken as significant. Data are reported as
group mean value 6 SD.
Results
The effects of inhaled NO on hemodynamic variables are
shown in Table 1. There were no significant effects of inhaled
NO on indirect indexes of systolic LV function (heart rate,
cardiac output, peak systolic pressure or peak positive dP/dt).
Diastolic variables including peak negative dP/dt, tau and
end-diastolic pressure were similarly unaffected by induced
NO. There was a significant decrease in end-diastolic pressure
(13.9 6 5.5 to 12.5 6 5.7 mm Hg, p , 0.05) and end-diastolic
volume (133.1 6 36.4 to 123.7 6 31.4 ml, p , 0.05) from
beginning to end of the study. These time-related decreases
were unaffected by delivery or withdrawal of inhaled NO.
Stroke volume and duration of electromechanical systole (con-
traction duration) were unaffected by inhaled NO.
Two load-independent indexes of contractile state (ESPVR
and PRSWR) were determined during IVCO. Four patients
were excluded from ESPVR calculations and two from
PRSWR calculations because of poor linear correlation coef-
ficients (r , 0.80) of individual IVCO runs in one or more of
the time periods. Adjusted r2 for the regression models was
0.95 and 0.91, respectively. There was no significant change in
the elastance (p 5 0.76) or intercept (p 5 0.43) for ESPVR or
slope (p 5 0.75) or intercept (p 5 0.73) for PRSWR, indicating
a lack of inotropic effect of inhaled NO across the entire group
(Table 2). Figure 1A shows an example of a series of pressure-
volume loops after a single IVCO in one patient during inhaled
NO. Figure 1B shows the complete data set for ESPVR,
PRSWR and EDPVR for the same patient resulting from
multiple IVCO runs. As can be seen, for both ESPVR and
PRSWR, the data during inhaled NO fall within the 95%
confidence intervals for control data before inhaled NO. There
was no change in the volume at operating pressure (V130) or
stroke work (V10,000) due to inhaled NO (Table 2). Therefore,
both methods of assessing contractility (ESPVR, PRSWR)
confirmed the absence of any negative inotropic effect of
inhaled NO.
Complete diastolic compliance measurements (before and
during inhaled NO) were available for eight subjects. Adjusted
r2 for the EDPVR model was 0.91. This lack of effect of
inhaled NO on LV chamber compliance in other patients is
confirmed by multiple linear regression analysis for the entire
group, which demonstrated that inhaled NO was not an
independent predictor of change in slope of the regression
Table 2. Effect of Inhaled Nitric Oxide on Load-Independent






Elastance (mm Hg/ml) 1.86 6 0.09 1.91 6 0.06 0.76
V0 (ml) 232.5 6 3.2 231.4 6 2.2 0.43
V130 (ml) 37.4 6 3.4 36.3 6 2.3
PRSWR
MSW (mm Hg) 98.3 6 2.8 103.1 6 2.3 0.75
V0SW (ml) 17.2 6 3.7 22.8 6 2.9 0.73
V10,000 (ml) 119.0 6 6.5 119.8 6 5.1
EDPVR
Compliance (ml/mm Hg) 8.12 6 0.34 8.63 6 0.43 0.43
P0 (mm Hg) 1.5 6 0.3 2.9 6 0.4 0.02
Data are shown as mean value 6 SE. EDPVR 5 end-diastolic pressure-
volume relation; ESPVR 5 end-systolic pressure-volume relation; MSW 5
PRSW slope; PRSWR 5 preload recruitable stroke work relation; P0 5 pressure
intercept at zero volume; V 5 volume intercept (V0 5 volume at zero pressure;
V130 5 volume at 130 mm Hg; V0SW 5 volume at zero stroke work; V10,000 5
volume at 10,000 mm Hgzml).





Heart rate (beats/min) 67.5 6 11.0 67.5 6 11.5 67.1 6 10.5
Cardiac output (liters/
min)
5.85 6 1.71 5.71 6 1.90 5.58 6 1.69
Systolic pressure (mm
Hg)
136.6 6 19.7 133.3 6 19.8 132.0 6 23.2
Peak positive dP/dt
(mm Hg/s)
1,279 6 262 1,252 6 215 1,199 6 163




13.9 6 5.5 13.3 6 5.2 12.5 6 5.7*
Peak negative dP/dt
(mm Hg/s)
21,409 6 428 21,395 6 352 21,392 6 299
Tau (ms) 51.9 6 9.9 50.9 6 9.6 51.2 6 10.2
Volumes
End-diastolic volume (ml) 133.1 6 36.4 128.8 6 38.2 123.7 6 31.4*
Stroke volume (ml) 88.3 6 28.7 86.4 6 31.6 84.7 6 28.3
*p , 0.05, before versus after nitric oxide inhalation. Data are shown as
mean value 6 SD. dP/dt 5 first derivative of left ventricular pressure; tau 5 time
constant of relaxation.
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equation (Table 2) (p 5 0.43). There was a small but statisti-
cally significant increase in pressure axis intercept from 1.5 6
0.3 mm Hg to 2.9 6 0.4 mm Hg (p 5 0.02). For the EDPVR
data set for the patient shown in Figure 1B, end-diastolic data
points before inhaled NO (pre a-wave end-diastolic pressure
and volume) were used to determine baseline linear diastolic
compliance regression curves (695% confidence intervals). As
can be seen for this patient, data during inhaled NO fall
entirely within the 95% confidence intervals.
In the subgroup of five patients who underwent right heart
catheterization, normal rest PVR was confirmed. There was no
significant increase in cardiac output (before inhaled NO
4.94 6 0.81 vs. during inhaled NO 5.22 6 1.06 liters/min, p 5
0.23) or change in PVR (before 122 6 38 vs. during 117 6 51
dyneszszcm25, p 5 0.78).
After 10 min of inhaled NO therapy, neither methemoglo-
bin or nitrate levels had increased significantly in either the LV
or the right atrium (Table 3) in nine patients. The levels in the
LV and right atrium were only marginally higher during NO
inhalation than at baseline. Confirmation of delivery of inhaled
NO was made by measurement of NO concentration at point
of delivery by using an electrochemical analyzer. There was no
difference between LV and right atrial methemoglobin and
nitrate levels at baseline or during inhaled NO delivery (Table
3).
Discussion
Because of its pulmonary vascular selectivity, and its low
toxicity when delivered at therapeutic concentrations, inhaled
NO is being increasingly used (7,9–11). Many patients receiv-
ing inhaled NO have had cardiac surgery (mitral valve, coro-
nary artery bypass, heart transplantation), where there may be
short-term reversible LV dysfunction related to cardiopulmo-
nary bypass. In these patients a direct negative inotropic effect
of inhaled NO could have significant consequences. Using the
same delivery system as in this study, we previously observed
two cases suggestive of a negative inotropic effect in severe left
heart failure where pulmonary vasodilation induced by inhaled
NO was associated with a decrease in cardiac output. In these
cases, the elevation in pulmonary capillary wedge pressure
could not be explained by increased pulmonary flow (reported
in part [15]). Bocchi et al. (16) described three cases in which
inhaled NO led to pulmonary edema, emphasizing the potential
for hemodynamic deterioration in the presence of chronically
impaired LV function. Despite this clinical and previous experi-
mental (4,5) evidence for myocardial effects of inhaled NO, we
found no negative inotropic effect from supplemental NO deliv-
ered by inhalation when we used load-independent indexes to
measure LV chamber function in vivo. Furthermore, we found no
change in active relaxation as assessed by tau, no alteration in
peak negative dP/dt and no alteration in LV diastolic compliance.
Figure 1. A, Example of a series of pressure-volume loops
after inferior vena cava occlusion (IVCO) in a single patient
during NO inhalation. B, Same patient. Complete data set for
ESPVR, PRSWR and EDPVR during multiple IVCO runs.
The solid lines represent linear regression before NO inha-
lation 6 95% confidence intervals (dotted lines). Data during
NO inhalation are represented by open triangles for ESPVR
and PRSWR and by open circles for EDPVR. As can be seen
in this patient, for ESPVR, PRSWR and EDPVR, the data
during NO inhalation fall within the 95% confidence intervals
for control data.
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Ventricular effects of inhaled NO. Elevation of pulmonary
wedge pressure is one of the major hemodynamic changes seen
with inhaled NO in patients with impaired LV function, but
inhaled NO did not increase LV end-diastolic pressure in this
study. There was a small but significant rise in pressure axis
intercept in the EDPVR, suggesting that the diastolic relation
was shifted upward, without any change in the slope (Table 2);
this finding would be consistent with a small loading effect on
the left ventricle without intrinsic change in diastolic tone (Fig.
2). We did not find any change in PVR in the small subgroup
of patients with normal LV function given inhaled NO. Previ-
ous studies (8,14) have shown that any increase in cardiac
output or decrease in PVR is proportional to the underlying
severity of pulmonary hypertension. The results of the present
study suggest that the elevation in wedge pressure during
inhaled NO in patients with heart failure is most likely related
to an increase in LV preload secondary to decreased PVR in
patients unable to respond by increasing LV output, rather
than to any adverse effect of inhaled NO on inotropic or
lusitropic state or on diastolic compliance. A similar conclusion
was reached in a study (29) that investigates the mechanism of
pulmonary wedge pressure elevation in patients with LV
dysfunction by using load-independent indexes of contractility
after intravenous adenosine administration.
There is firm evidence for both negative chronotropic and
inotropic effects of NO in isolated papillary muscle (3,18) and
myocardial cell (2,17,30) preparations. These in vitro experi-
ments were recently confirmed in the in vivo setting in normal
(4) and impaired (5) human hearts. Hare et al. (5) also suggested
that some of the downregulation of beta-responsiveness in
dilated cardiomyopathy may be explained by negative inotropic
modulation by NO. NO has also been implicated in the cardiac
dysfunction associated with cardiomyopathy (31), cardiac re-
jection (32,33) and sepsis (18). In addition, increased inducible
NO synthase expression and activity have been reported
(31,34) in states of dilated cardiomyopathy and myocarditis.
Systemically administered nitrates (which function as NO
donors) induce concomitant changes in ventricular preload
and afterload that may confound interpretation of direct
myocardial effects of NO. Paulus et al. (21) found that NO, in
the form of bicoronary nitroprusside infusion, decreased peak
systolic pressure, end-diastolic pressure and duration of con-
traction. This abbreviation of contraction may have been
related to alterations in afterload, independent of a direct
myocardial effect. In an attempt to account for systemic effects,
Paulus et al. also gave a right atrial nitroprusside infusion to a
subset of patients and found that similar but smaller decreases
in peak systolic pressure still occurred. The effect of right atrial
infusion on contraction duration in this subgroup was not
reported. Notwithstanding these limitations, ex vivo experi-
ments in guinea pig cardiac myocytes (30) and isolated hearts
with constant loading conditions (35) support the findings of
Paulus et al. No abbreviation of contraction was found in our
study, where afterload did not change. Similar to the study of
Paulus et al., we found an absence of NO effect on other
indirect indexes of LV function (peak positive dP/dt, ejection
fraction).
Inactivation of NO in vivo. The discordance between ex-
perimental inotropic and lusitropic effects of NO and the
absence of such effects in this study are most likely related to
the rapid inactivation of free NO. Whereas the half-life of NO
in vitro is ;6 s, its half-life in vivo is ,1 because of binding and
inactivation by hemoglobin (6,36). This is thought to be the
basis of the pulmonary vascular selectivity of inhaled NO (6).
In the nine patients who had metabolites of NO measured, we
found no difference between LV and right atrial methemoglo-
bin or nitrate levels. This finding would be consistent with
inactivation of NO before it reaches the LV cavity and
coronary arteries, possibly in the pulmonary circulation or
veins. Had there still been free NO in the ventricular blood
pool, right atrial metabolite levels may have been expected to
be higher than those for the LV. The lack of significant rise in
levels in response to delivery of inhaled NO is not unsurprising
given the low concentration used. Indeed, analysis of data
published by Wennmalm and coworkers (37) shows that met-
hemoglobin did not increase significantly until after 20 min of
delivery of 25 ppm of inhaled NO and it then continued to
increase with time. Although coronary sinus sampling is often
used to document delivery and metabolism of physiologic
mediators (21,26), it is less appropriate in this setting, where
the agent is being delivered by inhalation. Because of the
Figure 2. EDPVR for a patient demonstrating the increase in pressure
offset without any change in slope during NO inhalation (INO). The
data points are derived from a point immediately preceding the a wave
and a point occurring at 10% of the filling volume earlier on the same
loop. This reflects LV diastolic properties during slow filling before
atrial contraction. The dashed line represents linear regression of data
before NO inhalation and 95% confidence intervals (CI, dotted lines).
Data during NO inhalation are represented by the open circles and the
solid line.
Table 3. Nitric Oxide Metabolites Sampled From the Left Ventricle
and Right Atrium Before and at 10 Minutes of 20 ppm of Inhaled
Nitric Oxide
Methemoglobin (%) Nitrate (mmol/liter)
LV RA LV RA
Baseline 0.26 6 0.10 0.27 6 0.11 39 6 25 38 6 26
Inhaled NO 0.29 6 0.16 0.28 6 0.18 41 6 27 38 6 26
Data are shown as mean value 6 SD. LV 5 left ventricle; NO 5 nitric oxide;
RA 5 right atrium.
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reported short half-life of NO, metabolites would be expected
to be formed before NO arrived in the LV cavity, as found in
this study.
Nitric oxide has also been shown (38,39) to bind to proteins
other than hemoglobin to form nitrosothiol groups. Although
the metabolic fate of NO bound to either hemoglobin or
plasma thiol groups is probably oxidation to NO3
2 (40), these
carriers may release active NO (39) or have intrinsic activity
without NO release (38,41) at remote sites such as the
coronary vasculature. The half-lives of nitrosothiols are much
longer than that of free NO (39), which may be compatible
with having a cardiac effect without systemic vascular effect in
persons with either impaired left heart function or enhanced
myocardial inducible NO synthase activity. Recent work (42)
also suggests that the contribution of higher oxides of nitrogen
may induce significant venodilation if inhaled NO is delivered
in sufficiently elevated concentrations.
Limitations of the study. Interpretation of this study is
limited by the normal LV function of our study patients. As the
negative inotropic effect of NO is most apparent in states of
sympathetic activation (2,5), a lack of inotropic effect in this
study may not be immediately extrapolated to patients with
congestive heart failure. Nevertheless, it is likely that the lack
of effect of inhaled NO on inotropic or lusitropic state or on
diastolic compliance was related to inactivation of free NO
before its arrival in the LV. Thus, a similar lack of inotropic
effect would be expected to be found in patients with impaired
heart function. Furthermore, because patients with LV dys-
function have less contractile reserve and may be more reliant
on sympathetic drive to maintain cardiac output, they are more
sensitive to alterations in loading conditions. In that situation,
the decreased PVR induced by inhaled NO may be expected to
increase the end-diastolic volume, with a consequent increase
in LV end-diastolic pressure without a change in diastolic
compliance or inotropic state. This hypothesis was confirmed
(43) in a canine model of cardiomyopathy with the use of
volume catheter load-independent indexes of LV chamber
function. Nevertheless, the absence of effects of inhaled NO on
inotropic state, lusitropic state and diastolic compliance in
patients with abnormal LV function has yet to be confirmed
directly with the use of load-independent techniques.
A further limitation of this study is in the small time-
dependent decrease of volume measurements from baseline
(before inhaled NO) to those obtained after inhaled NO
(Table 1). There are several possible explanations for this
observation. 1) Because all patients were studied immediately
after coronary angiography, the gradual decay in blood con-
ductivity due to ionic contrast elimination may have affected
the volumes recorded. 2) Gradual settling of the volume
catheter within the ventricle over repeated IVCO runs may
have decreased measured volumes. Because each IVCO is
associated with slight longitudinal displacement of the volume
catheter into the aorta with restitution after deflation of the
inferior cava balloon, it may be that over the course of the
study there was a small but systematic dislodgment toward
the aorta with each IVCO. 3) The diuretic effect of the contrast
medium may have decreased the intravascular volume and
therefore the end-diastolic volume. A drift in volume measure-
ments in several patients before administration of inhaled NO
suggests that any cumulative effect of inhaled NO or nitroso-
thiols is unlikely. The advantage of the load-independent
indexes employed in this study is that, despite these alterations
in preload volume with time, valid load-independent conclu-
sions concerning contractility and chamber compliance can still
be obtained.
A final limitation of this study is the lack of measurement of
either free NO or NO adducts. Although the methemoglobin
and nitrate constitute the majority of the metabolic pathway
for free NO produced in the body (37), other NO adducts not
measured may have accumulated during delivery of inhaled
NO. The results presented are consistent with the possibility
that NO is still circulating as an active adduct but without
affecting normal cardiac function.
Conclusions. In summary, inhaled NO does not affect
normal human LV performance. This lack of effect is most
likely to be related to rapid inactivation of NO in transit to the
heart. Despite clinical evidence of elevation of pulmonary
capillary wedge pressure in patients with impaired left heart
function, it seems likely that this elevation is related to
increased preload volume secondary to decreased PVR rather
than to a direct effect on the myocardium. Further studies
examining the effect of inhaled NO on ventricular inotropic
and lusitropic states and diastolic compliance in patients with
congestive heart failure and secondary pulmonary hyperten-
sion are needed.
We gratefully acknowledge the assistance of the staff of the St. Vincent’s
Hospital Cardiac Catheterisation Laboratory.
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